Biofrontera Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
120 PRESIDENTIAL WAY,, WOBURN, MA, 01801
Mailing Address
120 PRESIDENTIAL WAY,, WOBURN, MA, 01801
Phone
781-245-1325
Fiscal Year End
1231
EIN
473765675
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 19, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | March 6, 2026 | View on SEC |
Annual Reports
10-K
March 19, 2026
- Sales grew 12% to $28.5 million in 2025, showing Ameluz® is gaining market share.
- Completed enrollment for a Phase 3 trial for Ameluz® in basal cell carcinoma, with top results expected in late 2026, signaling potential market expansion.
Material Events
8-K
Strategy Change
March 19, 2026
High Impact
- Biofrontera Inc. reported record sales of $10.3 million for Q4 2025, a significant increase from $7.6 million last year.
- The company achieved a profit of $5.6 million in Q4 2025, a major turnaround from a $5.0 million loss in Q4 2024.
8-K
Financial Distress
January 7, 2026
High Impact
- Biofrontera Inc. received a Nasdaq warning notice for failing to maintain a minimum stock price of $1.00.
- The company's stock traded below $1.00 for 34 consecutive business days, triggering the non-compliance notice.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.